Andrew Mclachlan

Biography

Dr. ANDREW MCLACHLAN is currently working as a Professor in the Department of Department of Pharmacy, University of Sydney , Australia. His research interests includes The impact of ageing on drug disposition and response to medicines. Includes clinical pharmacological studies in older people, assessing the manner in which age affects response to medicines, age-related patterns of using medications, and how these factors inform the quality use of medicines. Currently he is involved in a trial of deprescribing (i.e. judicious and appropriate cessation of) medications in older individuals. Ethnic differences in drug response. Collaborations with GSK studying the impact of geographical ancestry on the response to medicines, to help inform the safe use of medications and new drug development. Herb-drug interactions. Investigates the impact of herbal medicines on conventional medicines including insights related to the mechanism and consequences of these interactions. Therapeutic drug monitoring as a tool for optimised drug therapy. Current research focuses on antifungal treatments, aiming to individualise and guide optimal pharmacological endpoints by accounting for individual variability in response to these medications. Optimal anticoagulant use in older people. Includes the development and assessment of a collaborative model of home-based post-discharge warfarin management service, which was associated with a significantly reduced rate of readmissions and adverse events and improved persistence with therapy, and studies of herb-drug interactions with warfarin. Optimal treatment of low back pain. Series of collaborations on the efficacy of various interventions including physiotherapy, NSAIDs and paracetamol in low back pain, which led to two publications in the Lancet (2007 and 2014), BMJ (2015) and New England Journal of Medicine (2017). The research is now being extended to explore interventions in the management of sciatica and in defining the management model that best serves patients with acute low back pain in the primary care setting. Optimising anticancer therapies by understanding pharmacokinetic and pharmacodynamic variability. Quality use of medicines. Including the patterns of medicines use and how this relates to quality care and health outcomes in the area of mental health, cardiovascular disease and cancer. Quality and safety in medication management.. He /she is serving as an editorial member and reviewer of several international reputed journals. Dr. ANDREW MCLACHLAN is the member of many international affiliations. He/ She has successfully completed his Administrative responsibilities. He /she has authored of many research articles/books related to The impact of ageing on drug disposition and response to medicines. Includes clinical pharmacological studies in older people, assessing the manner in which age affects response to medicines, age-related patterns of using medications, and how these factors inform the quality use of medicines. Currently he is involved in a trial of deprescribing (i.e. judicious and appropriate cessation of) medications in older individuals. Ethnic differences in drug response. Collaborations with GSK studying the impact of geographical ancestry on the response to medicines, to help inform the safe use of medications and new drug development. Herb-drug interactions. Investigates the impact of herbal medicines on conventional medicines including insights related to the mechanism and consequences of these interactions. Therapeutic drug monitoring as a tool for optimised drug therapy. Current research focuses on antifungal treatments, aiming to individualise and guide optimal pharmacological endpoints by accounting for individual variability in response to these medications. Optimal anticoagulant use in older people. Includes the development and assessment of a collaborative model of home-based post-discharge warfarin management service, which was associated with a significantly reduced rate of readmissions and adverse events and improved persistence with therapy, and studies of herb-drug interactions with warfarin. Optimal treatment of low back pain. Series of collaborations on the efficacy of various interventions including physiotherapy, NSAIDs and paracetamol in low back pain, which led to two publications in the Lancet (2007 and 2014), BMJ (2015) and New England Journal of Medicine (2017). The research is now being extended to explore interventions in the management of sciatica and in defining the management model that best serves patients with acute low back pain in the primary care setting. Optimising anticancer therapies by understanding pharmacokinetic and pharmacodynamic variability. Quality use of medicines. Including the patterns of medicines use and how this relates to quality care and health outcomes in the area of mental health, cardiovascular disease and cancer. Quality and safety in medication management..

Research Interest

The impact of ageing on drug disposition and response to medicines. Includes clinical pharmacological studies in older people, assessing the manner in which age affects response to medicines, age-related patterns of using medications, and how these factors inform the quality use of medicines. Currently he is involved in a trial of deprescribing (i.e. judicious and appropriate cessation of) medications in older individuals. Ethnic differences in drug response. Collaborations with GSK studying the impact of geographical ancestry on the response to medicines, to help inform the safe use of medications and new drug development. Herb-drug interactions. Investigates the impact of herbal medicines on conventional medicines including insights related to the mechanism and consequences of these interactions. Therapeutic drug monitoring as a tool for optimised drug therapy. Current research focuses on antifungal treatments, aiming to individualise and guide optimal pharmacological endpoints by accounting for individual variability in response to these medications. Optimal anticoagulant use in older people. Includes the development and assessment of a collaborative model of home-based post-discharge warfarin management service, which was associated with a significantly reduced rate of readmissions and adverse events and improved persistence with therapy, and studies of herb-drug interactions with warfarin. Optimal treatment of low back pain. Series of collaborations on the efficacy of various interventions including physiotherapy, NSAIDs and paracetamol in low back pain, which led to two publications in the Lancet (2007 and 2014), BMJ (2015) and New England Journal of Medicine (2017). The research is now being extended to explore interventions in the management of sciatica and in defining the management model that best serves patients with acute low back pain in the primary care setting. Optimising anticancer therapies by understanding pharmacokinetic and pharmacodynamic variability. Quality use of medicines. Including the patterns of medicines use and how this relates to quality care and health outcomes in the area of mental health, cardiovascular disease and cancer. Quality and safety in medication management.